Scientists Discover a Cholesterol Pathway That Kills Ovarian Cancer Cells
Every April, tens of thousands of cancer researchers descend on one city for the American Association for Cancer Research annual meeting. This year it was San Diego, April 17–22. It’s part science fair, part family reunion, and it’s where a lot of ideas get their first public airing years before they reach a clinic.
One of the findings that came out of it, from a lab at the University of Florida, is about something you have almost certainly been told to worry about for entirely different reasons: cholesterol.
Why a cancer cell cares about cholesterol
Cholesterol has a bad reputation it only partly deserves. Yes, too much of the wrong kind clogs arteries. But cholesterol is also a building material — it’s a structural component of the membrane around every single cell in your body. Think of it as the mortar between bricks. Without it, the wall doesn’t hold.
Now think about what a cancer cell does for a living. It divides. Constantly. Every time one cell becomes two, it has to build an entire new membrane from scratch. A tumor that’s doubling itself is, among other things, a construction site with an enormous and unrelenting demand for mortar.
Your body makes cholesterol on an assembly line — a chain of chemical steps, each run by its own enzyme, each handing off to the next. Statins, the cholesterol drugs millions of people take, work by jamming a machine near the start of that line.
The University of Florida team, led by Shuang Huang, PhD, a professor in the Department of Physiology and Aging, went looking further down the line. They focused on an enzyme called SQLE.
Stopping growth versus causing death
Here’s the distinction that makes this finding interesting, and it’s one worth understanding because it shows up all over cancer treatment.
Some drugs are cytostatic — they stop cancer cells from growing. The cells are still alive; they’re just frozen. Other drugs are cytotoxic — they actually kill the cells.
It sounds like a technicality. It isn’t. A frozen cancer cell is a cancer cell that has time. Time to accumulate mutations, time to find a workaround, time to wait out the drug and start growing again the moment pressure lets up. That’s a big part of how resistance develops — the thing that turns a treatment that worked into a treatment that used to work.
When Huang’s team blocked SQLE in the lab, the ovarian cancer cells didn’t just stop dividing. They died.
As Huang put it: “If you treat cancer with a drug that causes cell death, it’s harder for the cancer to develop resistance.” A dead cell can’t adapt. A dead cell can’t come back in eighteen months wearing a disguise.
What actually kills them
The mechanism has a wonderfully descriptive name: lipotoxicity. Fat poisoning.
Here’s the ELI5. If you jam the assembly line at the very beginning — the statin approach — the whole line just goes quiet. Not much gets made, and not much goes wrong.
But if you jam it in the middle, the machines upstream keep working. Raw material keeps flowing in and piling up in front of the blockage, with nowhere to go. Imagine a factory conveyor belt where you remove one station: parts keep arriving and stack up until the pile becomes the problem. In a cell, those piled-up fatty intermediates are toxic. The cell essentially poisons itself with its own half-finished cholesterol.
The graduate student Cheng Chi led this arm of the work — worth noting, because the person actually running these experiments is usually someone in the early years of their career, funded by grants that are never guaranteed.
The second discovery: a different way to die
A companion study from the same lab, presented by Mahmuda Akter, looked at another route to cancer cell death entirely: ferroptosis.
Cells have several different ways of dying, and they’re not interchangeable. The famous one is apoptosis — programmed cell death, the cell’s built-in self-destruct button. Most chemotherapy tries to press that button. And a great many cancers have learned to disable it. Pressing a broken button harder doesn’t help.
Ferroptosis is a completely separate mechanism, and it depends on iron. Here’s the picture: the membranes around your cells are made partly of fats, and fats can go rancid. Iron accelerates that spoiling. Normally cells keep a cleanup crew on duty that mops up the damage before it spreads. Ferroptosis is what happens when that crew is overwhelmed — the spoiling runs away with itself, the membrane falls apart, and the cell disintegrates.
Why does that matter? Because it’s a different button. A cancer cell that has spent years learning to ignore the apoptosis signal has no particular defense against having its membranes rust through. It’s like a burglar who has studied the front door lock, only to have someone come in through the roof.
The UF team is now working with medicinal chemists on campus to turn these findings into drug candidates that could eventually be tested in people.
Warming up a “cold” tumor
The lab is also chasing a third thread, and it connects to why immunotherapy has historically underperformed in ovarian cancer.
Researchers describe tumors as “hot” or “cold.” A hot tumor is crawling with immune cells — the immune system has noticed it and shown up. Drugs that release the immune system’s brakes work well here, because there’s already an army at the gates waiting to be let in.
A cold tumor is one the immune system has essentially failed to notice. Immunotherapy struggles, not because the brakes are the problem, but because nobody came to the fight. Ovarian cancer has a long, frustrating history of running cold.
Here’s the connection: how a cell dies changes whether the immune system pays attention. A quiet, tidy death goes unremarked. A messy, inflammatory death — membranes rupturing, contents spilling — sets off alarms and draws immune cells in. So if you can force ovarian cancer cells to die loudly, you might be able to turn a cold tumor hot, and make immunotherapies that don’t currently work start working.
That’s the hypothesis the UF lab is testing. It’s a good one.
The honest caveat
We want to be careful here, because hope is precious and we don’t want to spend yours carelessly.
This work was done in cells and preclinical models, not in people. The road from “kills cancer cells in a dish” to “helps a woman in a clinic” is long, and most candidates don’t survive it. There is no SQLE inhibitor you can ask your oncologist for this month.
The team’s next step is testing SQLE inhibitors alongside an FDA-approved drug that blocks cholesterol absorption — a sensible pincer move, cutting off both the cholesterol the cell makes and the cholesterol it takes in. That’s still laboratory work.
Why we’re telling you anyway
Because this is what the earliest stage of hope actually looks like, and we think you deserve to see it rather than only hearing about things once they’ve been approved.
Somewhere in Gainesville, a graduate student found a way to make ovarian cancer cells poison themselves. Down the hall, a colleague found a way to make them rust apart from the inside. Both approaches sidestep the exact defenses that make this disease so hard to treat.
Neither will help anyone this year. Both are the reason there will be something new to write about in five.
If you’re in treatment now, the practical version of this article is simpler: ask your care team what trials you’re eligible for. Today’s clinical trials were somebody’s AACR poster a few years ago — and today’s posters are the trials your daughters may one day be offered.
Sources